Immunocore Holdings plc

IMCR

Immunocore Holdings plc

IMCR

Insider Sentiment (TTM):

Last Purchase:2025-03-17Last Sale:2026-02-18Shares Purchased (TTM):0Shares Sold (TTM):124,380

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:48,758,989Shares Outstanding:50,754,763Institutional Ownership Pct.:96.07%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	485	453	468	498	488	477	456	538	505	833	443
Marketable Securities Current	395	392	396	394	395	360	365	364	355	-	0
Contract With Customer Receivable After Allowance …	95	81	74	76	70	63	63	64	60	58	52
Prepaid Expense And Other Assets Current	68	70	50	49	44	42	41	36	34	31	30
Income Tax Receivable	-	-	2	-	-	-	0	-	-	-	-
Inventory Net	8	8	7	6	5	7	5	5	3	4	5
Assets Current	1,051	1,004	997	1,023	1,002	949	930	1,006	957	926	529
Property Plant And Equipment Net	13	12	11	9	10	10	10	9	8	8	9
Operating Lease Right Of Use Asset	37	38	39	39	39	38	38	40	32	33	34
Deferred Income Tax Assets Net	-	-	0	14	14	14	15	13	10	11	11
Other Assets Noncurrent	18	19	20	16	17	17	17	17	16	16	14
Assets	1,119	1,072	1,067	1,103	1,082	1,028	1,010	1,085	1,023	994	597
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	26	30	24	23	24	29	25	20	20	16	18
Accrued Liabilities And Other Liabilities	206	207	220	145	144	118	186	197	164	139	120
Contract With Customer Liability Current	1	1	1	1	1	-	0	-	-	-	0
Operating Lease Liability Current	2	2	2	2	2	2	2	1	1	1	1
Notes And Loans Payable Current	-	-	-	-	-	-	-	48	-	-	-
Liabilities Current	235	240	247	170	170	149	212	266	185	155	139
Accounts Payable And Accrued Liabilities Noncurren…	-	-	-	97	84	62	-	3	2	2	1
Contract With Customer Liability Noncurrent	4	5	5	5	5	6	5	6	5	5	6
Operating Lease Liability Noncurrent	39	40	42	41	43	41	40	41	33	34	36
Long Term Notes And Loans	394	394	393	393	392	392	391	390	438	438	48
Liabilities	700	678	686	706	694	650	649	707	664	634	228
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	1,273	1,247	1,240	1,228	1,216	1,202	1,190	1,181	1,174	1,164	1,150
Retained Earnings Accumulated Deficit	-819	-818	-831	-801	-801	-791	-796	-772	-781	-769	-745
Accumulated Other Comprehensive Income Loss Net Of…	-34	-35	-28	-30	-27	-33	-34	-31	-34	-35	-36
Stockholders Equity	420	394	381	397	388	378	361	378	359	360	369
Liabilities And Stockholders Equity	1,119	1,072	1,067	1,103	1,082	1,028	1,010	1,085	1,023	994	597
Common Stock Par Or Stated Value Per Share	0.002	0.002	0.002	0.002	0.002	0.002	0.002	0.002	0.002	0.002	0.002
Common Stock Shares Issued	51	51	51	50	50	50	50	50	50	50	50
Shares Outstanding	51	51	51	50	50	50	50	50	50	50	50

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-5.99%	0.49%	13.90%	-	-	-	-	-	-	-	-	-
2025	22.33%	4.01%	17.55%	0.91%	6.55%	3.68%	25.02%	14.35%	11.13%	-7.00%	-2.21%	-12.78%
2024	-20.12%	-44.73%	-34.56%	-5.38%	-17.19%	-13.50%	-2.30%	-12.92%	-1.52%	-3.12%	-7.67%	-1.30%
2023	-	-	-	-	-	-	-	-	-	-8.24%	-19.55%	-23.00%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31
Liquidity Ratios
Current Ratio	4.47	4.18	4.04	6.00	5.89	6.36	4.38	3.78	5.17	5.96	3.80
Quick Ratio	4.15	3.86	3.81	5.68	5.60	6.03	4.16	3.62	4.97	5.73	3.56
Working Capital	815.85M	763.69M	750.05M	852.50M	832.22M	799.46M	717.68M	739.66M	771.76M	770.75M	389.80M
Leverage & Debt
Debt to Equity	1.67	1.72	1.80	1.78	1.79	1.72	1.80	1.87	1.85	1.76	0.62
Interest Coverage TTM	-1.85	-2.83	-3.73	-2.79	-2.67	-2.55	-3.74	-4.32	-	-	-
Debt Ratio	0.62	0.63	0.64	0.64	0.64	0.63	0.64	0.65	0.65	0.64	0.38
Efficiency & Turnover
Asset Turnover TTM	0.39	0.39	0.39	0.35	0.34	0.33	0.39	0.21	-	-	-
Per Share Metrics
Diluted EPS TTM	-0.35	-0.52	-0.71	-0.58	-0.40	-0.42	-1.02	-0.52	-	-	-
Free Cash Flow Per Share TTM	-0.54	-0.61	-0.30	0.06	0.56	0.52	0.42	0.77	-	-	-
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-
Margin Metrics
Gross Profit Margin TTM	101.10%	101.14%	101.27%	100.71%	100.74%	100.99%	100.88%	-	-	-	-
Operating Profit Margin TTM	-5.24%	-8.35%	-11.34%	-11.88%	-13.04%	-14.27%	-22.71%	-22.56%	-	-	-
Net Profit Margin TTM	-4.20%	-6.68%	-8.88%	-7.70%	-5.70%	-6.48%	-16.47%	-12.08%	-	-	-
Growth Metrics
Net Revenue Growth (1Y)	20.95%	23.75%	28.95%	67.85%	-	-	-	-	-	-	-
Net Income Growth (1Y)	-11.02%	27.46%	-30.48%	6.99%	-	-	-	-	-	-	-
EPS Growth (1Y)	-12.20%	25.78%	-30.97%	6.18%	-	-	-	-	-	-	-
Valuation Metrics
P/E TTM	-89.54	-55.51	-49.21	-62.66	-77.70	-68.71	-28.87	-57.01	-	-	-
P/B TTM	3.86	3.89	4.59	4.62	4.06	3.93	4.09	4.12	4.72	9.02	9.06
P/S TTM	3.76	3.71	4.37	4.82	4.43	4.45	4.75	6.89	-	-	-
Market Cap	1.62B	1.53B	1.75B	1.83B	1.58B	1.49B	1.47B	1.56B	1.69B	3.24B	3.34B
Enterprise Value	1.13B	1.08B	1.28B	1.33B	1.09B	1.01B	1.02B	1.02B	1.19B	2.41B	2.90B
Calculated Values
Free Cash Flow TTM	-27.45M	-30.75M	-15.05M	2.81M	28.31M	26.04M	20.89M	38.42M	-	-	-
Net Debt	-484.92M	-452.68M	-467.71M	-498.41M	-487.93M	-476.85M	-455.73M	-537.77M	-504.99M	-832.82M	-442.63M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-18Sale

Owner: Berman, David M

Title: HEAD OF R&D

Shares: 5,965

Price/Share: $32.35

Value: $192,967.75

Shares Owned: 5,859

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: St, Leger Tina Amber

Title: CHIEF HR OFFICER

Shares: 1,000

Price/Share: $32.35

Value: $32,350.00

Shares Owned: 1,119

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: Goll, John

Title: SVP, FINANCE & CAO

Shares: 698

Price/Share: $32.35

Value: $22,580.30

Shares Owned: 653

Relationship: Officer

Ownership: Direct

2026-02-18Sale

Owner: Jallal, Bahija

Title: CHIEF EXECUTIVE OFFICER

Shares: 11,474

Price/Share: $32.35

Value: $371,183.90

Shares Owned: 12,343

Relationship: Director,Officer

Ownership: Direct

2025-12-05Sale

Owner: Berman, David M

Title: HEAD OF R&D

Shares: 572

Price/Share: $40.14

Value: $22,960.08

Shares Owned: -

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-18	Berman, David M	Officer	HEAD OF R&D	Direct	Sale	5,965	32.35	$192,967.75	5,859	4
2026-02-18	St, Leger Tina Amber	Officer	CHIEF HR OFFICER	Direct	Sale	1,000	32.35	$32,350.00	1,119	4
2026-02-18	Goll, John	Officer	SVP, FINANCE & CAO	Direct	Sale	698	32.35	$22,580.30	653	4
2026-02-18	Jallal, Bahija	Director,Officer	CHIEF EXECUTIVE OFFICER	Direct	Sale	11,474	32.35	$371,183.90	12,343	4
2025-12-05	Berman, David M	Officer	HEAD OF R&D	Direct	Sale	572	40.14	$22,960.08	0	4
2025-11-28	Berman, David M	Officer	HEAD OF R&D	Direct	Sale	5,521	40.09	$221,336.89	0	4
2025-11-25	Berman, David M	Officer	HEAD OF R&D	Direct	Sale	18,020	40.03	$721,340.60	0	4
2025-09-30	Berman, David M	Officer	HEAD OF R&D	Direct	Sale	61,849	35.23	$2,178,940.27	0	4
2025-09-15	Berman, David M	Officer	HEAD OF R&D	Direct	Sale	200	35.01	$7,002.00	0	4
2025-09-11	Berman, David M	Officer	HEAD OF R&D	Direct	Sale	19,081	36.28	$692,258.68	0	4
2025-03-17	667,, L.P., Baker Felix, …	Director	-	Indirect	Purchase	807,338	29.65	$23,937,571.70	2,144,060	4
2024-04-01	St, Leger Tina Amber	Officer	CHIEF HR OFFICER	Direct	Sale	4,375	64.06	$280,262.50	0	4
2024-02-28	Berman, David M	Officer	HEAD OF R&D	Direct	Sale	36,509	69.16	$2,524,962.44	0	4
2024-02-27	Berman, David M	Officer	HEAD OF R&D	Direct	Sale	54,938	70.79	$3,889,061.02	0	4
2024-01-03	St, Leger Tina Amber	Officer	Chief HR Officer	Direct	Sale	4,375	70.16	$306,950.00	0	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

96.07%

Inst. Shares: 48,758,989

Shares Outstanding: 50,754,763

2025-12-31

87.24%

Inst. Shares: 43,921,446

Shares Outstanding: 50,345,666

2025-09-30

80.80%

Inst. Shares: 40,727,019

Shares Outstanding: 50,403,717

2025-06-30

77.29%

Inst. Shares: 38,873,767

Shares Outstanding: 50,294,205

2025-03-31

75.29%

Inst. Shares: 37,708,264

Shares Outstanding: 50,086,684

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	48,758,989	50,754,763	96.07%
2025-12-31	43,921,446	50,345,666	87.24%
2025-09-30	40,727,019	50,403,717	80.80%
2025-06-30	38,873,767	50,294,205	77.29%
2025-03-31	37,708,264	50,086,684	75.29%
2024-12-31	36,016,409	49,991,064	72.05%
2024-09-30	35,691,759	50,021,939	71.35%
2024-06-30	36,243,021	50,014,086	72.47%
2024-03-31	35,783,759	49,877,218	71.74%
2023-12-31	31,901,453	48,888,975	65.25%
2023-09-30	32,615,944	48,888,975	66.71%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Immunocore Holdings plc (IMCR) — SEC Financial Statements & Analysis

Immunocore Holdings plc (IMCR) is a biological products, (no diagnostic substances) company, incorporated in X0. Immunocore Holdings plc trades on Nasdaq as: IMCR. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Immunocore Holdings plc reported a 20.95% year-over-year revenue growth, a Gross Profit Margin of 101.10% (TTM), a Debt-to-Equity ratio of 1.67x, a Price-to-Sales (P/S) ratio of 3.76x (TTM), a Price-to-Book (P/B) ratio of 3.86x (TTM), at a market cap of $1.62B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 20.95%
Gross Profit Margin TTM: 101.10%
Debt To Equity: 1.67x
P/S TTM: 3.76x
P/B TTM: 3.86x
Market Cap: $1.62B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Immunocore Holdings plc in?

Immunocore Holdings plc (IMCR) operates in the Biological Products, (No Diagnostic Substances) industry.

What is IMCR's market cap?

Immunocore Holdings plc (IMCR) has a market capitalization of $1.62B as of 2026-06-30.

What exchange does IMCR trade on?

Immunocore Holdings plc (IMCR) trades on the Nasdaq.

Where is Immunocore Holdings plc incorporated?

Immunocore Holdings plc is incorporated in United Kingdom.